DK1309324T3 - Antikonvulsive derivater egnede til behandling og forebyggelse af udvikling af type II diabetes mellitus og syndrom X - Google Patents

Antikonvulsive derivater egnede til behandling og forebyggelse af udvikling af type II diabetes mellitus og syndrom X

Info

Publication number
DK1309324T3
DK1309324T3 DK01958878T DK01958878T DK1309324T3 DK 1309324 T3 DK1309324 T3 DK 1309324T3 DK 01958878 T DK01958878 T DK 01958878T DK 01958878 T DK01958878 T DK 01958878T DK 1309324 T3 DK1309324 T3 DK 1309324T3
Authority
DK
Denmark
Prior art keywords
convulsive
syndrome
prevention
treatment
type
Prior art date
Application number
DK01958878T
Other languages
Danish (da)
English (en)
Inventor
Carlos Plata-Salaman
Jeffrey Crooke
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of DK1309324T3 publication Critical patent/DK1309324T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK01958878T 2000-07-07 2001-07-06 Antikonvulsive derivater egnede til behandling og forebyggelse af udvikling af type II diabetes mellitus og syndrom X DK1309324T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21714100P 2000-07-07 2000-07-07
US27002201P 2001-02-20 2001-02-20

Publications (1)

Publication Number Publication Date
DK1309324T3 true DK1309324T3 (da) 2006-06-12

Family

ID=26911655

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01958878T DK1309324T3 (da) 2000-07-07 2001-07-06 Antikonvulsive derivater egnede til behandling og forebyggelse af udvikling af type II diabetes mellitus og syndrom X

Country Status (22)

Country Link
US (2) US6852701B2 (enExample)
EP (1) EP1309324B1 (enExample)
JP (1) JP4920163B2 (enExample)
CN (1) CN101404993A (enExample)
AR (1) AR032465A1 (enExample)
AT (1) ATE320805T1 (enExample)
AU (1) AU2001280486A1 (enExample)
BR (1) BR0112519A (enExample)
CA (1) CA2415093A1 (enExample)
DE (1) DE60118206T2 (enExample)
DK (1) DK1309324T3 (enExample)
ES (1) ES2260261T3 (enExample)
HU (1) HUP0302307A3 (enExample)
IL (1) IL153713A0 (enExample)
MX (1) MXPA03000136A (enExample)
MY (1) MY126897A (enExample)
NO (1) NO20030064L (enExample)
NZ (1) NZ523531A (enExample)
PL (1) PL365680A1 (enExample)
PT (1) PT1309324E (enExample)
RU (1) RU2268720C2 (enExample)
WO (1) WO2002003984A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674776B2 (en) * 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
WO2004050081A1 (en) * 2002-12-02 2004-06-17 University Of Florida Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
JP4912312B2 (ja) * 2004-08-24 2012-04-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗痙攣薬として有用な新規なベンゾ−縮合ヘテロアリールスルファミド誘導体
CA2609185A1 (en) * 2005-05-20 2006-11-30 Ahmed F. Abdel-Magid Process for preparation of sulfamide derivatives
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070191459A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191453A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of substance abuse and addiction
AU2007253814A1 (en) * 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
WO2008027557A2 (en) 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
EP2394643B1 (en) 2006-11-17 2015-09-02 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
EP2363113B1 (en) * 2006-12-04 2017-08-02 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
ES2660170T3 (es) 2007-01-25 2018-03-21 NAIA Metabolic, Inc. Sensibilizadores a la insulina y métodos de tratamiento
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US8580298B2 (en) * 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
WO2010008776A2 (en) 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Disposable patch and reusable sensor assembly for use in medical device localization and mapping systems
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN102579367B (zh) 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
EP2829270B1 (en) 2012-03-23 2020-11-11 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Joint product containing synephrine and topiramate
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10278948B1 (en) 2015-09-03 2019-05-07 Tian Xia Method for transnasal delivery of anticonvulsant and therapeutic treatments

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
AU651244B2 (en) * 1991-09-19 1994-07-14 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
EP0915697B1 (en) * 1996-06-28 2002-09-18 Ortho-McNeil Pharmaceutical, Inc. Anticonvulsant sulfamate derivatives useful in treating obesity
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
NZ513643A (en) 1999-02-24 2005-04-29 Univ Cincinnati Use of sulfamate derivatives for treating impulse control disorders
AU4050100A (en) 1999-04-08 2000-11-14 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in maintaining weight loss
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
US6191163B1 (en) * 1999-04-08 2001-02-20 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in lowering lipids
WO2000076493A1 (en) 1999-06-14 2000-12-21 Thomas Najarian Combination therapy for effecting weight loss and treating obesity

Also Published As

Publication number Publication date
CA2415093A1 (en) 2002-01-17
US6852701B2 (en) 2005-02-08
EP1309324B1 (en) 2006-03-22
NO20030064L (no) 2003-03-06
MY126897A (en) 2006-10-31
AR032465A1 (es) 2003-11-12
HUP0302307A3 (en) 2007-05-29
US20020037861A1 (en) 2002-03-28
ES2260261T3 (es) 2006-11-01
DE60118206D1 (de) 2006-05-11
JP4920163B2 (ja) 2012-04-18
MXPA03000136A (es) 2004-09-13
NO20030064D0 (no) 2003-01-06
CN101404993A (zh) 2009-04-08
PL365680A1 (en) 2005-01-10
NZ523531A (en) 2005-07-29
JP2004510700A (ja) 2004-04-08
HUP0302307A2 (hu) 2003-10-28
AU2001280486A1 (en) 2002-01-21
WO2002003984A3 (en) 2003-03-06
PT1309324E (pt) 2006-06-30
US7109174B2 (en) 2006-09-19
WO2002003984A2 (en) 2002-01-17
RU2268720C2 (ru) 2006-01-27
BR0112519A (pt) 2004-03-30
EP1309324A2 (en) 2003-05-14
DE60118206T2 (de) 2006-12-14
IL153713A0 (en) 2003-07-06
ATE320805T1 (de) 2006-04-15
US20040209824A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
NO20030064D0 (no) Antikonvulsive derivater for anvendelse ved prevensjon av utvikling av typeII diabetes mellitus og syndrom X
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
DK1183020T3 (da) (3-trihalogenmethylphenoxy)(4-halogenphenyl) til behandling af insulinresistens og type 2-diabetes
DK1333887T3 (da) Kombinationsbehandling omfattende antidiabetiske og antikonvulsive midler
DK1329456T3 (da) Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme
NO20016314D0 (no) Blandinger og fremgangsmåte for oljefeltapplikasjoner
NO20043733L (no) Aryl-5-tio-Β-D-glukopyranosid-derivater og legemidler for diabetes inneholdende de samme
NL1016224A1 (nl) Foto-basevormend middel en foto-zuurvormend middel bevattende foto- etssamenstelling.
DK1250146T3 (da) Anvendelse af botulinumtoxin til behandling af diabetes
DK1143977T3 (da) 2-oxy-benzoxazinonderivater til behandling af obesitas
ATE297920T1 (de) Linezolid-krystall form ii
NO20022087D0 (no) Fremgangsmåte for behandling av diabetes
NO20025357D0 (no) Antranylamider og deres anvendelse som legemidler
DK1282719T3 (da) Fremgangsmåde til fremstilling af dihydroxyestere og derivater deraf
NO20030800L (no) Aminoalkylbenzoyl-benzofuran- eller benzotiofenderivater, fremgangsmåte forderes fremstilling og preparater inneholdende de samme
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
DK1228193T3 (da) Felint calicivirirus-gener og rekombinante vacciner der indeholder dem
NO20030759D0 (no) 10-aryl-11-HBENZO(b)fluorenderivater og analoger for medisinsk anvendelse
NO20035056D0 (no) Adenosinanaloger for behandling av insulinresistenssyndrom og diabetes
NO20011537D0 (no) Kjemokinreseptorpeptidvaksiner for behandling og forebygging av diabetes
IS7275A (is) Samsetning fyrir hollegg og notkun á henni
DK1456377T3 (da) Syn3-sammensætninger og fremgangsmåder
DE50112350D1 (de) Arzneimittel enthaltend aktiviertes antithrombin iii
DK1173436T3 (da) Thiazolidindionderivat og anvendelse deraf som antidiabetikum
IS6707A (is) Efnablanda til forvarna og meðhöndlunar á krabbameini